Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
The poster describes the results of SAPHYR study that assessed the safety and efficacy of sarilumab in PMR patients who flared on tapering glucocorticoid (GC) dose. The study met its primary endpoint with higher number of patients achieving sustained remission with sarilumab 200 mg Q2W + 14-week GC taper when compared with patients receiving placebo + 52-week GC taper.
Author(s):
- Dr. Robert Spiera, MD, Hospital for Special Surgery
- Sebastian Unizony
- Kenneth J. Warrington
- Jennifer Sloane Lazar
- Angeliki Glannelou
- Michael C Nivens
- Bolanie Akinlade
- Wanling Wong
- Yong Lin
- Frank R Buttgereit, MD
- Valerie Devauchelle-Pensec
- Andrea Rubbert-Roth
- Bhaskar Dasgupta
| Display Label | Action |
|---|